PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

Trial ID or NCT#

NCT03132636

Status

not recruiting iconNOT RECRUITING

Purpose

The primary objective is to estimate the objective response rate (ORR) for metastatic Basal Cell Carcinoma (BCC) (group 1) and for unresectable locally advanced BCC (group 2) when treated with cemiplimab as a monotherapy

Official Title

A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. * Confirmed diagnosis of invasive BCC* Progression of disease on hedgehog inhibitor (HHI) therapy or intolerance of prior HHI therapy* At least 1 measurable lesion* ≥18 years of age* Hepatic function, renal function, bone marrow function in defined lab-value-ranges* Anticipated life expectancy \>12 weeks* Consent to provide archived tumor biopsy material (all patients)* Group 2: consent to undergo research biopsies* Group 2: must not be a candidate for radiation therapy or surgery* Comply with study procedures and site visits* Sign Subject Information Sheet and Informed Consent Form
    1. Key
Exclusion Criteria:
  1. * Ongoing or recent significant autoimmune disease* Prior treatment with specific pathway-blockers (PD-1/PD-L1)* Prior treatment with immune-modulating agents within 28 days before cemiplimab* Untreated brain metastasis that may be considered active* Immunosuppressive corticosteroid doses (\>10mg prednisone) within 28 days prior to treatment with cemiplimab* Active infections requiring therapy, including HIV, hepatitis* Pneumonitis within the last 5 years* Cancer treatment other than radiation therapy, including investigational or standard of care, within 30 days prior to treatment with cemiplimab* Documented allergic reactions or similar to antibody treatments* Concurrent malignancies other than BCC, other than those with negligible risk of metastases or death* Any acute or chronic psychiatric problems* Having received a solid organ transplantation* Inability to undergo contrast radiological assessments* Breastfeeding, pregnant, women of childbearing potential not using contraception
    1. Note: Other protocol-defined inclusion/exclusion criteria apply
View All Criteria
Show Less

Investigator(s)

Anne Lynn S. Chang, MD
Anne Lynn S. Chang, MD
Dermatologist, General dermatologist, Dermatologic oncologist, Cutaneous oncology specialist
Professor of Dermatology

Contact us to find out if this trial is right for you.

Contact

Alexander Ayon Valencia
650-498-5185

View on ClinicalTrials.gov